Together with a group of academic and industrial experts, Liudmila Polonchuk proposes real-world data as a novel source to quantify pro-arrhythmic risk for translation of preclinical cardiac safety data to humans in a new upcoming regulatory paradigm aiming to advance drug candidates with maximum benefits and minimal risks for patients.
Copyright © 2022.